Bifeprunox

Experimental dopamine D2 receptor partial agonist researched as an antipsychotic agent From Wikipedia, the free encyclopedia

Bifeprunox (INN; code name DU-127,090) is an atypical antipsychotic which, similarly to aripiprazole, combines minimal D2 receptor agonism with serotonin receptor agonism.[1] It was under development for the treatment of schizophrenia, psychosis and Parkinson's disease.[2]

ATC code
  • none
CAS Number
PubChem CID
ChemSpider
Quick facts Clinical data, ATC code ...
Bifeprunox
Clinical data
ATC code
  • none
Identifiers
  • 7-[4-(biphenyl-3-ylmethyl)piperazin-1-yl]-1,3-benzoxazol-2(3H)-one
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC24H23N3O2
Molar mass385.467 g·mol−1
3D model (JSmol)
  • O=C2Oc1c(cccc1N2)N5CCN(Cc4cccc(c3ccccc3)c4)CC5
  • InChI=1S/C24H23N3O2/c28-24-25-21-10-5-11-22(23(21)29-24)27-14-12-26(13-15-27)17-18-6-4-9-20(16-18)19-7-2-1-3-8-19/h1-11,16H,12-15,17H2,(H,25,28) checkY
  • Key:CYGODHVAJQTCBG-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)
Close

In a multi-center, placebo-controlled study, 20 mg of bifeprunox was found to be significantly more effective than placebo at reducing symptoms of schizophrenia, with a low incidence of side effects.[3] An NDA for Bifeprunox was filed with the U.S. Food and Drug Administration in January 2007. The FDA rejected the application in August 2007.[4] In June 2009, Solvay and Wyeth decided to cease development because "efficacy data did not support pursuing the existing development strategy of stabilisation of non-acute patients with schizophrenia."[5]

Pharmacodynamics

Bifeprunox is an atypical antipsychotic that is a partial D2 agonist.

See also

References

Related Articles

Wikiwand AI